World Journal of Pharmaceutical
Science and Research

An International Peer Reviewed Journal for Science & Pharmacy Professional


Login | Registration


ISSN: 2583-6579


Impact Factor: 5.111

ABSTRACT

EFFECTIVENESS OF N ACETYLCYSTEINE AND TAURINE IN REDUCING MICROALBUMINURIA IN DIABETIC AND HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: A RETROSPECTIVE, OBSERVATIONAL STUDY

V. Mohan, V. Ashwin Karuppan, Subir Chandra Swar, Manojit Ketan Mukhopadhyay, Nanditha Arun, Debasis Basu, MC Deepaklal, Yash Patel, Mahendra Yashwant Sawant, Gayatri Veeramani Jayaraman*, Nagashankar N., Monjori Mitra

Background: Microalbuminuria is one of the earliest signs and a major risk factor for chronic kidney disease (CKD) progression, often aggravated by the concomitant presence of diabetes and/or hypertension. One of the major pathophysiological contributors to CKD is oxidative stress. The current study investigated the effectiveness of combination therapy with antioxidants N-acetylcysteine (NAC) and Taurine in reducing urinary albumin to creatinine ratio (uACR). Methods: In this retrospective study, data were analyzed from 305 adult diabetic and/or hypertensive patients diagnosed with CKD stage 1-3. All patients had microalbuminuria (uACR: 30-300mg/g) and were treated with NAC (150mg) + Taurine (500mg) (Nefrosave®) as an adjuvant therapy. The primary and secondary outcome measures included changes in uACR and the incidence of adverse events, respectively, from baseline to Day 90 of treatment. Results: The overall mean uACR reduced significantly from 131.13mg/g to 115.69mg/g (11.77%, p<0.001) after 90 days of treatment with NAC+Taurine. Reduction in mean uACR was also evident in subgroups of patients with both diabetes and hypertension (11.15%, p<0.001), diabetes alone (15.09%, p<0.001), and hypertension alone (8.31%, p=0.561), as well as amongst patients with CKD stage 1 (16.77%, p=0.002), stage 2 (14.45%, p<0.001) and stage 3 (5.19%, p=0.003). No adverse events were reported. Conclusion: The combination of NAC and Taurine could be an effective nephroprotective adjuvant therapy in reducing microalbuminuria in diabetic and/or hypertensive adult patients with CKD stage 1-3; Outcome was found to be better when treatment was initiated early.

[Full Text Article]

TRACK ARTICLE

NEWS

  • Impact Factor Increased

    We are pleased to inform you that our IMPACT FACTOR has increased from 3.454 to 5.111

    Email & SMS Alert

    We will provide you email alerts regarding New Issue Release, Publication of your Article, Invitaion for New Upcoming Issue, Manuscript releted Emails etc.

    April 2025 Issue Published

    Its Our pleasure to inform you that, WJPSR April 2025 Issue has been Published, Kindly check it on Click here

    Indexing

    This journal is indexed in world wide reputed commettee like: "DOI for all Articles" "Google Scholer" "SJIF Impact Factor:- 5.111" "Cosmos Impact Factor" "ISI Indexing" "International Impact Factor Services (IIFS)" "ResearchBib" etc.

    Article Invite for Publication

    Dear Researcher, Article Invited for Publication  in WJPSR Coming Issue.

    If you wish to Publish your Article in WJPSR Coming" April 2025 " Issue, 

    Submit it as soon as possible.